Search

A 31-year-old man with advanced-stage Duchenne muscular dystrophy (DMD) experienced a lack of efficacy during treatment with scopolamine for aspiration. The man had a history of recurrent aspiration pneumonia and chronic hypercapnia, leading to a tracheostomy and percutaneous endoscopic gastrostomy (PEG) tube placement. Despite receiving scopolamine, he continued to suffer from recurrent aspiration pneumonia. Eventually, he underwent a total laryngectomy, which resulted in a quick recovery, improved quality of life, and no recurrence of aspiration pneumonia. [Extracted from the article]

A 57-year-old woman experienced a lack of effectiveness in her treatment for dysphagia, a condition characterized by difficulty swallowing. The woman had developed dysphagia after a subarachnoid hemorrhage and subsequent complications. Despite receiving standard logopedic training and treatment with scopolamine, ipratropium bromide, and botulinum toxin, her swallowing training did not progress after six weeks. However, after undergoing pharyngeal electrical stimulation, her swallowing frequency sensitivity improved significantly, and she was able to be discharged with instructions to continue with a modified diet. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 34-year-old man exhibited lack of efficacy during treatment with scopolamine for acute abdominal pain and non-bloody diarrhoea. [Extracted from the article]

In a study involving 131 patients, two cases of medication errors were reported. In the first case, a child developed prolonged cytopenias after the caregiver continued to administer mercaptopurine despite being instructed to hold the medication. The second case involved a male child who developed temporary diplopia after accidentally getting scopolamine in his eyes. The therapy with mercaptopurine was discontinued in the first case, while the diplopia resolved in the second case. [Extracted from the article]

Healthcare professionals should be aware of the possible confusion between scopolamine and butylscopolamine when prescribing, dispensing and administering the drugs. Butylscopalamine is indicated for the treatment of acute spasms of gastrointestinal, biliary and genitourinary tracts; but scopolamine is indicated as premedication in anaesthesia to reduce excessive salivation and respiratory tract secretions. Scopolamine and butylscopolamine mix-ups have been reported in Spain, according to a safety report published in the I WHO Pharmaceuticals Newsletter i . [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event An 18-year-old man developed central nervous system stimulation syndrome during treatment with fentanyl, ondansetron and scopolamine for scrotal pain or as general anaesthesia [ I not all routes, dosages and duration treatments to reaction onset stated i ]. Fentanyl/ondansetron/scopolamine: Central nervous system stimulation syndrome: case report The CNS stimulation syndrome was attributed to general anaesthetics i.e. fentanyl and ondansetron and anticholinergic toxicity of scopolamine. [Extracted from the article]

In addition, he developed palpitations discomfort during treatment with scopolamine, and palpitations and respiratory discomfort during treatment with atropine; further, he experienced inefficacy during treatment with scopolamine and atropine for abdominal pain due to cholinergic syndrome. Therefore, beginning from the ninth course, scopolamine was discontinued and replaced with atropine [atropine sulfate] 0.5mg before and after irinotecan infusion. Moreover, both scopolamine and atropine monotherapy were ineffective in alleviating abdominal pain due to cholinergic syndrome. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event * Drug overdose In a case series of two patients registered in the National pharmacovigilance database and notified to the Regional Pharmacovigilance Center in France, a 48-year-old man developed flushing, bilateral mydriasis, itchy conjunctival hyperaemia and blurred vision following off-label atropine overdose due to inadvertent administration of entire single-dose container by nurse for silorrhoea, and a 45-year-old man developed bilateral mydriasis, urine retention and drug toxicity following treatment with scopolamine for silorrhoea and off-label atropine overdose [ I not all duration of treatments to reaction onsets and outcomes stated i ]. His atropine and scopolamine treatment were immediately stopped, and he was clinically monitored for the suspected anticholinergic toxicity with atropine overdose. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 46-year-old man experienced nausea following withdrawal of scopolamine for motion sickness. He had a travel history to the United States, where he developed nausea following a bus trip, typical of his motion sickness. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event * Drug overdose A 51-year-old woman developed unreactive mydriasis, alteration of the level of consciousness, hallucinations, chronic vasculopathy following scopolamine overdose and poisoning [ I amount for overdose not stated i ]. Lab investigations showed no abnormalities and urine drug screening immunoassay was negative. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 63-year-old woman developed anaphylactic shock secondary to scopolamine butylbromide [butylscopolamine bromide] use. Oxygen supplementation was provided via nose, but oxygen saturation further decreased to 72%. Subsequently, blood tests were performed, which showed elevated levels of plasma histamine and serum tryptase one hour after the onset of anaphylactic shock. [Extracted from the article]

A woman [ I exact age not stated i ] developed anticholinergic syndrome due to scopolamine intoxication, following involuntary exposure to scopolamine. Thereafter, liquid chromatography with high-resolution mass spectrometry showed that the urine sample contained 56 µg/L of scopolamine along with the presence of the metabolites nor-scopolamine and hydroxy-scopolamine. [Extracted from the article]

A 65-year-old woman experienced sedation during treatment with scopolamine hydrobromide. Thereafter, she received scopolamine hydrobromide [hyoscine hydrobromide; I dosage and route not stated i ]. B Author comment: b I "[Scopolamine hydrobromide] was discontinued after a single dose, as it caused profound sedation." i. [Extracted from the article]

The analysis reported that his blood scopolamine level was 7 ng/mL and the urine scopolamine level was 510 ng/mL. Four days later, toxicology screening was requested by the police to analyse the blood and urine samples collected at T 3.5h and those collected at T 14h. [Extracted from the article]

A 4-year-old boy developed aniscoria during treatment with scopolamine [ I therapeutic indication not specified i ]. The boy, who had creatine transporter deficiency with a mild torticollis, recurrent epistaxis and a tendency to salivate excessively, brought to a hospital due to a sudden onset of unreactive and dilated left pupil. After discussion with his mother, scopoderm patch was considered to be the most likely cause of his dilated pupil and no further investigations were felt necessary [ I duration of treatment to reaction onset not stated i ]. [Extracted from the article]

The article presents a case study of a man who experienced various toxicities, such as agitated delirium, confusion, and dilated pupils, after an overdose with scopolamine.

The article presents a case study of a 34-year-old woman who developed unilateral mydriasis and blurred vision due to accidental exposure to scopolamine.

The article presents a case study of a 17-year-old girl who developed aggravation of acute intermittent porphyria (AIP) resulting in death after treated with scopolamine and phenytoin as she suffered abdominal cramps and vomiting following a religious fasting.

The article presents a case study of a patient who developed tachycardia after scopolamine butylbromide injection.

An abstract of the article "Practitioners in nursing homes can also report drug adverse effects after occupational exposure!" by N. Petitpain and colleagues is presented.

The article presents a case study of a 75-year-old woman who developed toxic megacolon, haemorrhage and Pneumocystis pneumonia following treatment with prednisolone, scopolamine butylbromide, and tacrolimus for severe ulcerative colitis.

The article describes the case of a 39-year-old man suffering from paranoid schizophrenia who developed neuroleptic malignant syndrome (NMS) while being treated with antipsychotics and scopolamine hydrobromide for hypersalivation. The regular medication being received by the patient is noted. All his antipsychotic drugs were discontinued, however, the man's condition deteriorated with the relapse of eczema, which worsened with his mental illness's progression.

The article describes the case of a man who developed neuroleptic malignant syndrome while receiving scopolamine hydrobromide for hypersalivation.

The article describes the case of a four-year-old boy who developed delirium while undergoing transdermal scopolamine therapy.

The article describes the case of two women who experienced migraine-type headaches while undergoing treatment with scopolamine butylbromide.

An abstract is presented for the article "Manic after taking a vacation" by E, Tan and others, published in the journal "Current Psychiatry" in April 2016.

An abstract of the article "Hypersensitivity to butylscopolamine: A case report" by F.J. Iglesias-Souto and others is presented.